Sensory Enhancement Programs for Preterm Infants
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how different sensory programs in the NICU (neonatal intensive care unit) can aid the brain development of very preterm infants. Researchers use MRI scans to determine when and why brain injuries occur and how the brain develops in these infants. The goal is to assess whether early MRIs can predict which babies might benefit most from specific treatments, such as the SENSE-plus program (Supporting and Enhancing NICU Sensory Experiences 2nd Edition), and how these treatments impact their recovery both in the short and long term. The trial seeks very preterm infants born before 33 weeks, weighing between 0.5 and 4.5 kg, and in stable condition in the NICU. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could enhance care for future preterm infants.
Do I need to stop my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the clinical care team overseeing the trial.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that the SENSE II program, which enhances sensory experiences for premature babies in the NICU, is generally well-tolerated. Studies have found that this program provides safe and positive sensory experiences for infants. Existing research has reported no serious side effects from the interventions. The program offers sensory experiences tailored to the infants' age and needs, prioritizing their safety. Although specific safety data is limited, the program's nature suggests a low risk of harm.12345
Why are researchers excited about this trial?
Researchers are excited about these sensory enhancement programs because they aim to enrich the early developmental environment for preterm infants, who often face unique challenges. Unlike the standard care, which primarily focuses on medical stability, the SENSE-plus and SENSE programs integrate specific sensory experiences to promote brain development. These programs offer a structured approach to sensory exposure, which could potentially lead to better neurological outcomes by enhancing the infants' sensory environment during a critical period of brain growth.
What evidence suggests that the SENSE II program could be effective for preterm infants?
Research shows that the SENSE II program, a treatment in this trial, is designed to create positive sensory experiences for premature babies in the NICU. Studies have found that this program helps improve brain development in these infants. The SENSE II program provides structured, age-appropriate sensory activities, crucial for the brain growth of preterm babies. Early results suggest that involving families in these activities can enhance the babies' growth and development. By focusing on consistent, research-backed sensory inputs, the program aims to support the delicate developmental needs of these infants. Participants in this trial may receive either the SENSE II program or standard care, which serves as the control group.12346
Who Is on the Research Team?
Carmina Erdei, MD
Principal Investigator
Brigham and Women's Hospital and Harvard Medical School
Are You a Good Fit for This Trial?
This trial is for very preterm infants currently in the BWH NICU, born before 33 weeks of gestation and weighing between 0.5-4.5 kg who are stable according to their care team. Infants with congenital anomalies, genetic syndromes, or TORCH infections cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive serial brain MRI scans approximately every 2 weeks to monitor brain growth and evolution of injury throughout NICU hospitalization
Follow-up
Participants are monitored for neurodevelopmental outcomes and family functioning at NICU discharge and up to 2 years corrected age
What Are the Treatments Tested in This Trial?
Interventions
- Reference/ Standard of care
- SENSE-plus: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program
- SENSE: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor
POM Wonderful LLC
Industry Sponsor